AstraZeneca and UPMC Health Plan Form Unique Outcome Based Agreement

UPMC Health Plan and AstraZeneca today announced the initiation of a pioneering value-based contract effective Jan.1, 2019 for UPMC for Life Medicare members who are prescribed Brilinta (ticagrelor), a medication used to lower a patient's chances of having another heart attack or dying from one in the 12 months following a heart attack.